BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 27860216)

  • 21. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment strategies for mosaic overgrowth syndromes of the PI3K-AKT-mTOR pathway.
    Morin G; Canaud G
    Br Med Bull; 2021 Dec; 140(1):36-49. PubMed ID: 34530449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
    Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
    Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTOR mutations in Smith-Kingsmore syndrome: Four additional patients and a review.
    Gordo G; Tenorio J; Arias P; Santos-Simarro F; García-Miñaur S; Moreno JC; Nevado J; Vallespin E; Rodriguez-Laguna L; de Mena R; Dapia I; Palomares-Bralo M; Del Pozo Á; Ibañez K; Silla JC; Barroso E; Ruiz-Pérez VL; Martinez-Glez V; Lapunzina P
    Clin Genet; 2018 Apr; 93(4):762-775. PubMed ID: 28892148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism.
    Yeung KS; Tso WWY; Ip JJK; Mak CCY; Leung GKC; Tsang MHY; Ying D; Pei SLC; Lee SL; Yang W; Chung BH
    Mol Autism; 2017; 8():66. PubMed ID: 29296277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
    Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
    Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and genetic analysis of patients with segmental overgrowth features and somatic mammalian target of rapamycin (mTOR) pathway disruption: Possible novel clinical issues.
    Romano F; Madia F; De Marco P; Ognibene M; Guerrisi S; Scala M; Iacomino M; Baldassari S; Vercellino N; Manunza F; Tallone R; Pavanello M; Piatelli G; Garaventa A; Zara F; Capra V
    Birth Defects Res; 2022 Dec; 114(20):1440-1448. PubMed ID: 36345927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
    Chen J; Zhao KN; Li R; Shao R; Chen C
    Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoglycemia due to PI3K/AKT/mTOR signaling pathway defects: two novel cases and review of the literature.
    Maines E; Franceschi R; Martinelli D; Soli F; Lepri FR; Piccoli G; Soffiati M
    Hormones (Athens); 2021 Dec; 20(4):623-640. PubMed ID: 33876391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
    Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.
    Mirzaa GM; Rivière JB; Dobyns WB
    Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):122-30. PubMed ID: 23592320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy.
    Javadinia SA; Shahidsales S; Fanipakdel A; Mostafapour A; Joudi-Mashhad M; Ferns GA; Avan A
    Curr Pharm Des; 2018; 24(39):4646-4651. PubMed ID: 30636576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
    Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
    Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
    Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
    Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent studies on PI3K/AKT/mTOR signaling pathway in hematopoietic stem cells].
    Zhang YC; Cheng T; Yuan WP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):245-9. PubMed ID: 23484729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.